ONO 1301

Known as: ONO-1301 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
0246819972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND ONO-1301, a novel sustained-release prostacyclin agonist, has an anti-fibrotic effect on the lungs, heart, and kidneys… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Injury to the heart can result in cardiomyocyte hypertrophy, fibrosis, and cell death. Myocarditis sometimes progresses to… (More)
Is this relevant?
2012
2012
Tubulointerstitial injuries are crucial histological alterations that predict the deterioration of renal function in chronic… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
ONO-1301, a synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, promotes the production of hepatocyte… (More)
Is this relevant?
2011
2011
Diabetic nephropathy is the most common pathological disorder predisposing end-stage renal disease. ONO-1301 is a novel sustained… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2011
2011
OBJECTIVES The aim of this study was to prepare poly(lactide-co-glycolide) (PLGA) microspheres containing ONO-1301, a novel long… (More)
Is this relevant?
2009
2009
Impairment of cardiac function in cardiomyopathy has been postulated to be related to decreased blood flow and increased collagen… (More)
Is this relevant?
2007
2007
It has been shown previously that administration of angiogenic growth factors as genes or proteins can augment collateral growth… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
The balance between prostacyclin and thromboxane A2 (TXA2) plays an important role in pulmonary homeostasis. However, little… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1997
1997
The antinephritic effects of ONO-1301 ([7,8-dihydro-5-[(E)-[[a-(3-pyridyl)benzylidene]-aminooxy]ethyl]-1 -naphtyloxy]acetic acid… (More)
Is this relevant?